Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

DONALD P HURLEY

Allopathic & Osteopathic Physicians Family Medicine

NPI
1043206410
CMS profile
46816
Location
CHARLESTON, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$2,023.96

101 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $2,023.96 101

By paying entity

PY2021 · entire year · sorted by reported total

Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

DONALD P HURLEY

NPI 1043206410 · CMS profile ID 46816

Allopathic & Osteopathic Physicians / Family Medicine

CHARLESTON, SC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043206410?year=2021&recipient=provider&page=3#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
DONALD P HURLEY, NPI 1043206410, CMS profile ID 46816. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043206410?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). DONALD P HURLEY, NPI 1043206410, CMS profile ID 46816. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043206410?year=2021&recipient=provider&page=3#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
DONALD P HURLEY, NPI 1043206410, CMS profile ID 46816, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 3 of 3; records 101–101 of 101 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1043206410?year=2021&recipient=provider&page=3#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

101 matching records · $2,023.96 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 101 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 101–101 of 101.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Boehringer Ingelheim Pharmaceuticals, Inc. $14.9201/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 763351972 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,637.39 91
PY2020 $1,817.69 89
PY2021 $2,023.96 101
PY2022 $4,198.41 112
PY2023 $3,798.24 93
PY2024 $1,750.46 69
PY2025 $1,844.25 62

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,237,017.72 79
PY2024 Principal investigator $75,410.43 5
PY2023 Principal investigator $14,859.90 2
PY2021 Principal investigator $13,692.00 1
PY2020 Recipient $4,470.00 3
PY2020 Principal investigator $130,888.23 45
PY2019 Recipient $2,230.21 4
PY2019 Principal investigator $410,557.10 117

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

79 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Seqirus USA Inc $319.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269340
Principal investigator 1 Seqirus USA Inc $638.55 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269342
Principal investigator 1 Seqirus USA Inc $994.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269344
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269346
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269348
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269350
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269352
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269354
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269356
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269358
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269360
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269362
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269364
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269366
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269368
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269370
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269372
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269374
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269376
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269378
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269380
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269382
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269384
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269386
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269388
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269390
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269392
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269394
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269396
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269398
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269400
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269402
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269404
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269406
Principal investigator 1 Seqirus USA Inc $2,884.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269408
Principal investigator 1 Seqirus USA Inc $638.55 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269410
Principal investigator 1 Seqirus USA Inc $319.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269412
Principal investigator 1 Seqirus USA Inc $319.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269414
Principal investigator 1 Seqirus USA Inc $319.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269416
Principal investigator 1 Seqirus USA Inc $319.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269418
Principal investigator 1 Seqirus USA Inc $319.95 12/19/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185269420
Principal investigator 1 Eli Lilly and Company $6,317.00 11/25/2025 Non-covered Recipient Entity
WAKE RESEARCH ASSOCI
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF MUVALAPLIN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE HAD A PRIOR ATHEROSCLEROTIC CARDIOVASCULAR EVENT OR ARE AT RISK FOR A FIRST ATHEROSCLEROTIC CARDIOVASCULAR EVENT – MOVE-LP(A) No dispute reported 06/30/2026 1187893464
Principal investigator 1 Seqirus USA Inc $854.80 11/21/2025 Non-covered Recipient Entity
Charleston Clinical Trials
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250811138
Principal investigator 1 Seqirus USA Inc $234.90 11/21/2025 Non-covered Recipient Entity
Charleston Clinical Trials
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250811143
Principal investigator 1 Seqirus USA Inc $5,128.80 11/04/2025 Non-covered Recipient Entity
Charleston Clinical Trials
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250811124
Principal investigator 1 Seqirus USA Inc $1,409.40 11/04/2025 Non-covered Recipient Entity
Charleston Clinical Trials
A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults 65 Years of Age No dispute reported 06/30/2026 1250811132
Principal investigator 1 Seqirus USA Inc $1,500.00 10/27/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185270756
Principal investigator 1 Seqirus USA Inc $2,500.00 10/27/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185270766
Principal investigator 1 Seqirus USA Inc $9,500.00 10/27/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185270770
Principal investigator 1 AstraZeneca Pharmaceuticals LP $24,568.00 09/19/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH
a phase III,randomised,double blind,placebo controlled,event driven study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on renal outcomes and cardiovascular mortality in participants with chronic kidney disease and high blood pressure No dispute reported 06/30/2026 1185550651
Principal investigator 1 Seqirus USA Inc $111.30 09/10/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185270722
Principal investigator 1 Seqirus USA Inc $177.19 09/10/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185270736
Principal investigator 1 Seqirus USA Inc $1,183.50 09/10/2025 Non-covered Recipient Entity
M3 Wake Research, Inc
A Phase 3/3b Randomized Observer-blind Multicenter Clinical Study to Evaluate the Efficacy Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine Compared to a Non-Influenza Vaccine in Adults >=50 Years of Age No dispute reported 06/30/2026 1185270750
Principal investigator 1 ModernaTX, Inc. $408.33 07/28/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010240
Principal investigator 1 AstraZeneca Pharmaceuticals LP $27,270.10 07/09/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185550648
Principal investigator 1 ModernaTX, Inc. $10,838.88 06/27/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010226
Principal investigator 1 ModernaTX, Inc. $58,391.19 06/27/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010258
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $44,694.63 06/18/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH CHARLESTON
A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214123938
Principal investigator 1 AstraZeneca Pharmaceuticals LP $1,250.00 06/13/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185550645
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,036.00 05/30/2025 Non-covered Recipient Entity
WR-MSRA LLC
A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS No dispute reported 06/30/2026 1185550643
Principal investigator 1 ModernaTX, Inc. $700.00 05/19/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010228
Principal investigator 1 ModernaTX, Inc. $52,266.24 04/28/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010230
Principal investigator 1 ModernaTX, Inc. $23,549.76 04/28/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010234
Principal investigator 1 ModernaTX, Inc. $40,622.40 04/28/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010244
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,390.50 04/02/2025 Non-covered Recipient Entity
AGA CLINICAL TRIALS
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185550641
Principal investigator 1 ModernaTX, Inc. $6,667.00 03/20/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010246
Principal investigator 1 ModernaTX, Inc. $500.00 03/20/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010254
Principal investigator 1 ModernaTX, Inc. $1,881.00 03/20/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010256
Principal investigator 1 ModernaTX, Inc. $42.90 03/19/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010248
Principal investigator 1 ModernaTX, Inc. $1,547.00 03/19/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010250
Principal investigator 1 ModernaTX, Inc. $22,164.48 01/31/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010232
Principal investigator 1 ModernaTX, Inc. $104,299.65 01/31/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010236
Principal investigator 1 ModernaTX, Inc. $11,089.26 01/31/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010238
Principal investigator 1 ModernaTX, Inc. $9,345.35 01/31/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010242
Principal investigator 1 ModernaTX, Inc. $34,014.24 01/31/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010252
Principal investigator 1 ModernaTX, Inc. $44,099.64 01/31/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010260
Principal investigator 1 ModernaTX, Inc. $262,573.74 01/31/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH INC
A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ?50 Years of Age No dispute reported 06/30/2026 1253010262
Principal investigator 1 AstraZeneca Pharmaceuticals LP $12,000.00 01/03/2025 Non-covered Recipient Entity
WR-MSRA LLC
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185550639
Principal investigator 1 VERTEX PHARMACEUTICALS INCORPORATED $295,380.39 01/01/2025 Non-covered Recipient Entity
M3 WAKE RESEARCH CHARLESTON
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy No dispute reported 06/30/2026 1214123936